A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: A pediatric brain tumor consortium report

Neuro-Oncology

Volumn 16, Issue 12, 2014, Pages 1661-1668

  Su, Jack M ^a   Thompson, Patrick ^a   Adesina, Adekunle ^a   Li, Xiao Nan ^a   Kilburn, Lindsay ^b   Onar Thomas, Arzu ^c   Kocak, Mehmet ^d   Chyla, Brenda ^e   McKeegan, Evelyn ^e   Warren, Katherine E ^f   Goldman, Stewart ^g   Pollack, Ian F ^h   Fouladi, Maryam ⁱ   Chen, Alice ^j   Giranda, Vincent ^e   Boyett, James ^c   Kun, Larry ^c   Blaney, Susan M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Department of Surgery Children's National Medical Center   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e ABBVIE INC   (United States)

^f Pediatric Oncology Branch   (Germany)

^g Children's Hospital of Chicago Research Center   (United States)

^h CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

ⁱ Cincinnati Children's Hospital   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

ABT 888; CNS tumors; PARP inhibition; Pediatric phase I study; Veliparib

Indexed keywords

TEMOZOLOMIDE; VELIPARIB; ALKYLATING AGENT; BENZIMIDAZOLE DERIVATIVE; DACARBAZINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BRAIN STEM INFARCTION; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EPENDYMOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; PYRAMIDAL SIGN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR RECURRENCE; VOMITING; WEAKNESS; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; BRAIN NEOPLASMS; CLINICAL TRIAL; INFANT; METABOLISM; MONONUCLEAR CELL; MULTICENTER STUDY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZIMIDAZOLES; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DACARBAZINE; FEMALE; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; YOUNG ADULT;

EID: 84925969599     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou103     Document Type: Article

References (37)

1. O'Driscoll M, Jeggo PA. The role of double-strand break repair-insights from human genetics. Nat Rev Genet. 2006;7(1):45-54.
2. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol. 2003;4(6):435-445.
3. Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10(4):293-301.
4. De Murcia JM, Niedergang C, Trucco C, et al. Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A. 1997;94(14):7303-7307.
5. Ruscetti T, Lehnert BE, Halbrook J, et al. Stimulation of the DNA-dependent protein kinase by poly (ADP-ribose) polymerase. J Biol Chem. 1998;273(23):14461-14467.
6. Chalmers A, Johnston P, Woodcock M, et al. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys. 2004;58(2):410-419.
7. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res. 2006;34(6):1685-1691.
8. Barton VN, Donson AM, Kleinschmidt-De Masters BK, et al. PARP1 expression in pediatric central nervous system tumors. Pediatr Blood Cancer. 2009;53(7):1227-1230.
9. Smith SJ, Long A, Barrow JH, et al. Pediatric high-grade glioma: identification of poly (ADP-ribose) polymerase as a potential therapeutic target. Neuro Oncol. 2011;13(11):1171-1177.
10. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337-1344.
11. Van Vuurden DG, Hulleman E, Meijer OL, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget. 2011;2(12):984-996.
12. Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728-2737.
13. Palma JP, Wang YC, Rodriguez LE, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009;15(23):7277-7290.
14. Nowsheen S, Bonner JA, Yang ES. The poly (ADP-ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol. 2011;99(3):331-338.
15. Albert JM, Cao C, Kim KW, et al. Inhibition of poly (ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007;13(10):3033-3042.
16. Liu SK, Coackley C, Krause M, et al. A novel poly (ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol. 2008;88(2):258-268.
17. Barreto-Andrade JC, Efimova EV, Mauceri HJ, et al. Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther. 2011;10(7):1185-1193.
18. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009;27(16):2705-2711.
19. Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 2011;71(17):5626-5634.
20. Kummar S, Ji J, Morgan R, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012;18(6):1726-1734.
21. Isakoff SJ, Pulhalla S, Shepherd SP, et al. A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRCA2 mutation and metastatic breast cancer. Thirty-Fifth Annual CTRT-AACR San Antonio Breast Cancer Symposium. Cancer Res. 2012;72(24, suppl 3): Abstract #OT2-3-07.
22. Pishvaian MJ, Slack R, Witkiewicz A, et al. A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. 2011 ASCO Annual Meeting Proceedings. J Clin Oncol. 2011;29:(15, suppl):3502.
23. Muscal JA, Thompson PA, Giranda VL, et al. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010;65(3):419-425.
24. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007;110(7):1542-1550.
25. Baruchel S, Diezi M, Hargrave D, et al. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. Eur J Cancer. 2006;42(14):2335-2342.
26. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup study. J Clin Oncol. 2002;20(24):4684-4691.
27. Fouladi M, Stewart CF, Olson J, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2011;29(26):3529-3534.
28. Liu X, Palma J, Kinders R, et al. An enzyme-linked immunosorbent poly (ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem. 2008;381(2):240-247.
29. Kinders R, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv. 2007;7(6):325-334.
30. Ji J, Kinders RJ, Zhang Y, et al. Modeling pharmacodynamic response to the poly (ADP-ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One. 2011;6(10):e26152.
31. Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
32. Tutt A, Robson M, Garber JE, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-244.
33. McEllin B, Camacho CV, Mukherjee B, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly (ADP-ribose) polymerase inhibitors. Cancer Res. 2010;70(13):5457-5464.
34. Nowsheen S, Cooper T, Stanley JA, et al. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. PLoS One. 2012;7(10):e46614.
35. Neri P, Ren L, Gratton K, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood. 2011;118(24):6368-6379.
36. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
37. Huehls AM, Wagner JM, Huntoon CJ, et al. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly (ADP-ribose) polymerase inhibitor in a novel drug combination. Mol Pharmacol. 2012;82(4):767-776